Gilead Sciences (GILD) said its net income hit $3.66 billion in the second quarter, up from $772.6 million in the same quarter a year ago.

The company’s breakthrough hepatitis C drug Sovaldi – which cures the deadly liver disease in 90 percent of patients – fueled the profit hike, generating nearly six billion dollars in sales in just the first half of 2014, according to the earnings report.

After adjustments, earnings came to $2.36 per share, revenue more than doubled to $6.53 billion from $2.77 billion a year ago, while forecasted annual sales are pegged at $23 billion, all soaring past Wall Street forecasts.